Every 10-Q that ImageneBio, Inc. (IMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing therapies for immunological, autoimmune and inflammatory diseases. Its lead asset, IMG‑007 (olevaprubart), is a non-depleting anti‑OX40 monoclonal antibody initially targeted at atopic dermatitis and alopecia areata.
For the three months ended June 30, 2026, ImageneBio reported a net loss of $10,178 (in thousands), with research and development expenses of $6.7 million and general and administrative expenses of $5.1 million. Higher spending reflected expanding clinical work, public‑company costs, legal and IP activity, and stock‑based compensation.
For the six months ended June 30, 2026, net loss was $20,797 (in thousands). As of June 30, 2026, the company held $94,677 (in thousands) in cash and cash equivalents and $41,476 (in thousands) in marketable securities; management states this $136.2 million balance will fund operations for at least 12 months. In April 2026, a private placement of pre‑funded warrants raised $30.0 million to support development of olevaprubart while the company progresses a Phase 2b atopic dermatitis trial and prepares a Phase 2 alopecia areata study.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on immunological and inflammatory diseases, led by its anti-OX40 antibody IMG-007 for atopic dermatitis and alopecia areata. For the three months ended March 31, 2026, it reported a net loss of $10.6 million, compared with $6.1 million a year earlier, as research and development expenses rose to $6.0 million and general and administrative expenses increased to $6.1 million.
Cash, cash equivalents and marketable securities totaled $117.2 million as of March 31, 2026. In April 2026, the company raised an additional $30.0 million through a private placement of pre-funded warrants to purchase up to 5,770,335 shares of common stock at a purchase price of $5.199 per warrant share and an exercise price of $0.001 per share. Management believes this funding, together with existing resources, can support operations for at least 12 months.
The company completed a reverse merger with Ikena Oncology and divested its non-OX40 assets in 2025, leaving IMG-007 as its sole clinical asset. A multi-country Phase 2b dose-finding study in atopic dermatitis is underway, with topline data expected in the fourth quarter of 2027, and a Phase 2 study in alopecia areata is planned to start by the end of 2026, with initial data anticipated in 2028.
ImageneBio, Inc. (IMA) filed its Q3 2025 10‑Q and reported a transformative quarter driven by a reverse recapitalization with Ikena Oncology and a concurrent PIPE financing. The company ended September 30, 2025 with cash, cash equivalents and marketable securities of $142.6 million, positioning it to fund operations for at least the next 12 months.
For the quarter, ImageneBio recorded a net loss of $24.8 million, reflecting research and development expense of $15.6 million and general and administrative expense of $11.0 million as it advances its lead program, IMG‑007, a non‑depleting anti‑OX40 monoclonal antibody. For the nine months ended September 30, 2025, net loss totaled $38.4 million.
The July 25, 2025 reverse recapitalization brought in Ikena’s net assets (including $54.6 million of cash and $40.1 million of marketable securities) and the company raised additional capital via a 2,508,339‑share PIPE for approximately $75.0 million gross. A related $22.5 million pre‑merger term loan was forgiven at closing. ImageneBio also completed a Non‑OX40 divestiture, recording a related $7.5 million promissory note receivable and an offsetting CVR liability of $7.5 million. Shares outstanding were 11,181,672 as of November 3, 2025.